1089-R2 Search Results


recombinant human tnf rii/tnfrsf1b (aa 24-206) protein, cf  (Bio-Techne corporation)
89
Bio-Techne corporation recombinant human tnf rii/tnfrsf1b (aa 24-206) protein, cf
Recombinant Human Tnf Rii/Tnfrsf1b (Aa 24 206) Protein, Cf, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 89/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human tnf rii/tnfrsf1b (aa 24-206) protein, cf/product/Bio-Techne corporation
Average 89 stars, based on 1 article reviews
recombinant human tnf rii/tnfrsf1b (aa 24-206) protein, cf - by Bioz Stars, 2026-06
89/100 stars
  Buy from Supplier
rstnfr2  (R&D Systems)
92
R&D Systems rstnfr2
Recombinant and cell-derived sTNFR1 and sTNFR2 have a protective effect against TNFα-induced expression of pro-metastatic chemokines in MDA-MB-231 cells. MDA-MB-231 cells (MDA) were stimulated by TNFα (0.5 ng/mL) that was pre-incubated with rsTNFR1 (150 ng/mL), <t>rsTNFR2</t> (500 ng/mL), rsTNFR1 + rsTNFR2 (concentrations as before) or their vehicle. When indicated, the cells were cultured prior to TNFα stimulation with TAPI-0 (5 µg/mL) or its vehicle for 3 h, as well as during cytokine stimulation (TAPI-0 did not affect tumor cell growth). The concentrations of rsTNFR1 and rsTNFR2 were selected as described in . CM were collected following 24 h stimulation, and CXCL8 ( A ) and CXCL1 ( B ) levels were determined by ELISA. A representative experiment of n = 3 is presented. *** p < 0.001, ** p < 0.01, * p < 0.05. # p < 0.1. NS, not significant. Black asterisks denote the differences in chemokine levels between TNFα-stimulated cells and vehicle-treated cells. Orange asterisks denote the differences in chemokine levels between TAPI-0-treated cells and cells treated by its vehicle. Statistical analyses were performed as described in .
Rstnfr2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rstnfr2/product/R&D Systems
Average 92 stars, based on 1 article reviews
rstnfr2 - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier
human tnfr ii tnfrsf 1b immunoassay  (R&D Systems)
90
R&D Systems human tnfr ii tnfrsf 1b immunoassay
Figure 3. Kaplan-Meier curves illustrate progression-free sur- vival in subgroups of patients with (A) low and (B) high baseline levels of tumor necrosis factor receptor II <t>(TNFR</t> II).
Human Tnfr Ii Tnfrsf 1b Immunoassay, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human tnfr ii tnfrsf 1b immunoassay/product/R&D Systems
Average 90 stars, based on 1 article reviews
human tnfr ii tnfrsf 1b immunoassay - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Recombinant and cell-derived sTNFR1 and sTNFR2 have a protective effect against TNFα-induced expression of pro-metastatic chemokines in MDA-MB-231 cells. MDA-MB-231 cells (MDA) were stimulated by TNFα (0.5 ng/mL) that was pre-incubated with rsTNFR1 (150 ng/mL), rsTNFR2 (500 ng/mL), rsTNFR1 + rsTNFR2 (concentrations as before) or their vehicle. When indicated, the cells were cultured prior to TNFα stimulation with TAPI-0 (5 µg/mL) or its vehicle for 3 h, as well as during cytokine stimulation (TAPI-0 did not affect tumor cell growth). The concentrations of rsTNFR1 and rsTNFR2 were selected as described in . CM were collected following 24 h stimulation, and CXCL8 ( A ) and CXCL1 ( B ) levels were determined by ELISA. A representative experiment of n = 3 is presented. *** p < 0.001, ** p < 0.01, * p < 0.05. # p < 0.1. NS, not significant. Black asterisks denote the differences in chemokine levels between TNFα-stimulated cells and vehicle-treated cells. Orange asterisks denote the differences in chemokine levels between TAPI-0-treated cells and cells treated by its vehicle. Statistical analyses were performed as described in .

Journal: Cancers

Article Title: Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNFα Receptors in Human Triple-Negative Breast Cancer

doi: 10.3390/cancers14143513

Figure Lengend Snippet: Recombinant and cell-derived sTNFR1 and sTNFR2 have a protective effect against TNFα-induced expression of pro-metastatic chemokines in MDA-MB-231 cells. MDA-MB-231 cells (MDA) were stimulated by TNFα (0.5 ng/mL) that was pre-incubated with rsTNFR1 (150 ng/mL), rsTNFR2 (500 ng/mL), rsTNFR1 + rsTNFR2 (concentrations as before) or their vehicle. When indicated, the cells were cultured prior to TNFα stimulation with TAPI-0 (5 µg/mL) or its vehicle for 3 h, as well as during cytokine stimulation (TAPI-0 did not affect tumor cell growth). The concentrations of rsTNFR1 and rsTNFR2 were selected as described in . CM were collected following 24 h stimulation, and CXCL8 ( A ) and CXCL1 ( B ) levels were determined by ELISA. A representative experiment of n = 3 is presented. *** p < 0.001, ** p < 0.01, * p < 0.05. # p < 0.1. NS, not significant. Black asterisks denote the differences in chemokine levels between TNFα-stimulated cells and vehicle-treated cells. Orange asterisks denote the differences in chemokine levels between TAPI-0-treated cells and cells treated by its vehicle. Statistical analyses were performed as described in .

Article Snippet: To determine the impact of recombinant soluble (rs) TNFR1 and rsTNFR2 on induction of TNFα-induced chemokine production, rsTNFR1 (150 ng/mL, #636-R1, R&D Systems), rsTNFR2 (500 ng/mL, #1089-R2, R&D Systems), both of them together or a vehicle control were incubated with TNFα (0.5 ng/mL, #300-01A, PeproTech) for 60 min at room temperature.

Techniques: Recombinant, Derivative Assay, Expressing, Incubation, Cell Culture, Enzyme-linked Immunosorbent Assay

Recombinant and cell-derived sTNFR1 and sTNFR2 have a protective effect against TNFα-induced expression of pro-metastatic chemokines in BT-549 cells. BT-549 cells (BT) were stimulated by TNFα (0.25–0.5 ng/mL) that was pre-incubated with rsTNFR1 (150 ng/mL), rsTNFR2 (500 ng/mL), rsTNFR1 + rsTNFR2 (concentrations as before) or their vehicle. When indicated, the cells were cultured prior to TNFα stimulation with TAPI-0 (5 µg/mL) or its vehicle for 3 h, as well as during cytokine stimulation (TAPI-0 did not affect tumor cell growth). The concentrations of rsTNFR1 and rsTNFR2 were selected as described in . CM were collected following 24 h stimulation, and CXCL8 ( A ), CXCL1 ( B ) and CCL5 ( C ) levels were determined by ELISA. A representative experiment of n = 3 is presented. *** p < 0.001, ** p < 0.01, * p < 0.05, # p < 0.1. NS, not significant. Black asterisks denote the differences in chemokine levels between TNFα-stimulated cells and vehicle-treated cells. Orange asterisks denote the differences in chemokine levels between TAPI-0-treated cells and cells treated by its vehicle. Statistical analyses were performed as described in .

Journal: Cancers

Article Title: Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNFα Receptors in Human Triple-Negative Breast Cancer

doi: 10.3390/cancers14143513

Figure Lengend Snippet: Recombinant and cell-derived sTNFR1 and sTNFR2 have a protective effect against TNFα-induced expression of pro-metastatic chemokines in BT-549 cells. BT-549 cells (BT) were stimulated by TNFα (0.25–0.5 ng/mL) that was pre-incubated with rsTNFR1 (150 ng/mL), rsTNFR2 (500 ng/mL), rsTNFR1 + rsTNFR2 (concentrations as before) or their vehicle. When indicated, the cells were cultured prior to TNFα stimulation with TAPI-0 (5 µg/mL) or its vehicle for 3 h, as well as during cytokine stimulation (TAPI-0 did not affect tumor cell growth). The concentrations of rsTNFR1 and rsTNFR2 were selected as described in . CM were collected following 24 h stimulation, and CXCL8 ( A ), CXCL1 ( B ) and CCL5 ( C ) levels were determined by ELISA. A representative experiment of n = 3 is presented. *** p < 0.001, ** p < 0.01, * p < 0.05, # p < 0.1. NS, not significant. Black asterisks denote the differences in chemokine levels between TNFα-stimulated cells and vehicle-treated cells. Orange asterisks denote the differences in chemokine levels between TAPI-0-treated cells and cells treated by its vehicle. Statistical analyses were performed as described in .

Article Snippet: To determine the impact of recombinant soluble (rs) TNFR1 and rsTNFR2 on induction of TNFα-induced chemokine production, rsTNFR1 (150 ng/mL, #636-R1, R&D Systems), rsTNFR2 (500 ng/mL, #1089-R2, R&D Systems), both of them together or a vehicle control were incubated with TNFα (0.5 ng/mL, #300-01A, PeproTech) for 60 min at room temperature.

Techniques: Recombinant, Derivative Assay, Expressing, Incubation, Cell Culture, Enzyme-linked Immunosorbent Assay

Figure 3. Kaplan-Meier curves illustrate progression-free sur- vival in subgroups of patients with (A) low and (B) high baseline levels of tumor necrosis factor receptor II (TNFR II).

Journal: Cancer

Article Title: Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial.

doi: 10.1002/cncr.30845

Figure Lengend Snippet: Figure 3. Kaplan-Meier curves illustrate progression-free sur- vival in subgroups of patients with (A) low and (B) high baseline levels of tumor necrosis factor receptor II (TNFR II).

Article Snippet: Assays for serum TNFR II were conducted using an enzyme-linked immunosorbent assay with a commercially available human TNFR II/TNFRSF 1B Immunoassay (R&D Systems, Minneapolis, MN) according to the manufacturer’s recommendations.

Techniques: